Clinical trial
Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A)…
NCT00397215 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00397215 |
|---|---|
| Title | Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age |
| Official title | Evaluate Immunogenicity & Safety of a Single or Double-dose of the Pandemic Influenza Candidate Vaccine (GSK1562902A) Given Following a Two-administration Schedule (21 Days Apart) in Adults Over 60 Yrs |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not), Fluarix |
| Enrollment | 437 |
| Start date | Nov 17, 2006 |
| Primary completion | Sep 14, 2009 |
| Completion | Sep 14, 2009 |
| First posted | Nov 8, 2006 |
| Last update posted | Jun 10, 2019 |
| Countries | Belgium, Italy |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: